A Phase 3 interventional study of Tenapanor and Placebo in Constipation Predominant Irritable Bowel Syndrome, sponsored by Ardelyx. Completed at 111 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-04-21.
Sponsored by Ardelyx · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing tenapanor in Constipation — 3 open to participants now, 4 under way, 3 of them phase 3. tenapanor · Constipation.
Among the 11 studies testing tenapanor in Constipation, this one is the 2nd largest by enrollment, is one of 2 that started in 2015, is one of 7 in phase 3, and was the 3rd registered.
1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.
Browse Constipation studies →3 of the 11 studies testing tenapanor in Constipation are open now, in 1 country. Recruiting first, the newest first:
Ardelyx · Sites in United States
Ages 18–80
Cedar Valley Digestive Health Center · Sites in United States
Ages 50–89
Ardelyx · Sites in United States
Ages 6–18
By country, each count listing its studies:
tenapanor: first FDA approval 2019 (IBSRELA). What it is approved for, and how studies give it, is on its page →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 8
First in 2011; this study’s year is marked. 2 started in 2015.
This study's enrollment of 606 is above the median of 75 across 885 interventional studies indexed under Constipation.
Median enrollment 186 across the 11 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Ardelyx is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
Ardelyx has 9 studies filed under Constipation — fewer than ten, so there is no comparison to draw.
2 of the studies testing tenapanor in Constipation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07382167Phase 3ArdelyxA 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults | 2027-02-26 |
| NCT06460038Cedar Valley Digestive Health CenterTenapanor in Synucleinopathy-Related Constipation | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies testing tenapanor in Constipation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This phase 3, 12-week, randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of tenapanor in subjects with constipation-predominant irritable bowel syndrome (IBS-C) as defined by the ROME III criteria and who have active disease as determined after a two-week screening period. Subjects who qualify and are randomized into the study will either receive 50mg BID of tenapanor or placebo BID for 12 week treatment period and then undergo a 4 week placebo controlled randomized withdrawal.
During the 12-week treatment period, subjects will record daily assessments including: frequency and timing of bowel movements; sensation and complete bowel emptying; consistency of bowel movements; degree of straining, worst abdominal pain, abdominal discomfort, abdominal bloating, abdominal fullness and abdominal cramping. Subjects will also record weekly assessments including: adequate relief of IBS severity, and constipation severity.
At the end of the 12-week treatment period, there will be a 4-week randomized withdrawal period in which subjects who complete the study in Tenapanor group will be randomized to either Tenapanor 50mg BID or placebo BID (1:1) and subjects who complete the study in the placebo group will be assigned to receive Tenapanor 50mg BID.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tenapanor
Drug: Tenapanor
Placebo
Drug: Placebo
Also known as: RDX5791, AZD1722
6 of 12 Week Overall Responder Rate
An overall responder is defined as a weekly responder for the first 6/12 weeks where both CSBM and abdominal pain response criteria were met for the week. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?" The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.
Time frame: 12 weeks
6 of 12 Week Overall Complete Spontaneous Bowel Movement (CSBM)Responder Rate
An overall CSBM responder is defined as a weekly responder for the first 6/12 weeks. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?"
Time frame: 12 weeks
6 of 12 Week Overall Abdominal Pain Responder Rate
An overall abdominal pain responder is defined as a weekly responder for the first 6/12. The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.
Time frame: 12 weeks
9 of 12 Week Overall Responder Rate
An overall responder is defined as a weekly responder for the first 9/12 weeks where both CSBM and abdominal pain response criteria were met for the week. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline and a minimum of at least 3 CSBMs that same week. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?" The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.
Time frame: 12 weeks
9 of 12 Week Overall CSBM Responder Rate
An overall CSBM responder is defined as a weekly responder for the first 9/12 weeks. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline and a minimum of at least 3 CSBMs that same week. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?"
Time frame: 12 weeks
9 of 12 Week Overall Abdominal Pain Responder Rate
An overall abdominal pain responder is defined as a weekly responder for the first 9/12 weeks. The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.
Time frame: 12 weeks
| Milestone | 50mg BID | Placebo |
|---|---|---|
| Started | 307 | 299 |
| Completed | 261 | 272 |
| Not completed | 46 | 27 |
| Milestone | 50mg BID | Placebo |
|---|---|---|
| Started | 261 | 272 |
| Completed | 250 | 260 |
| Not completed | 11 | 12 |
An overall responder is defined as a weekly responder for the first 6/12 weeks where both CSBM and abdominal pain response criteria were met for the week. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?" The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.
| Participants | 50mg BID | Placebo |
|---|---|---|
| 6 of 12 Week Overall Responder Rate | 83 | 56 |
An overall CSBM responder is defined as a weekly responder for the first 6/12 weeks. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?"
| Participants | 50mg BID | Placebo |
|---|---|---|
| 6 of 12 Week Overall Complete Spontaneous Bowel Movement (CSBM)Responder Rate | 104 | 88 |
An overall abdominal pain responder is defined as a weekly responder for the first 6/12. The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.
| Participants | 50mg BID | Placebo |
|---|---|---|
| 6 of 12 Week Overall Abdominal Pain Responder Rate | 135 | 99 |
An overall responder is defined as a weekly responder for the first 9/12 weeks where both CSBM and abdominal pain response criteria were met for the week. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline and a minimum of at least 3 CSBMs that same week. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?" The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.
| Participants | 50mg BID | Placebo |
|---|---|---|
| 9 of 12 Week Overall Responder Rate | 42 | 10 |
An overall CSBM responder is defined as a weekly responder for the first 9/12 weeks. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline and a minimum of at least 3 CSBMs that same week. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?"
| Participants | 50mg BID | Placebo |
|---|---|---|
| 9 of 12 Week Overall CSBM Responder Rate | 52 | 15 |
An overall abdominal pain responder is defined as a weekly responder for the first 9/12 weeks. The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.
| Participants | 50mg BID | Placebo |
|---|---|---|
| 9 of 12 Week Overall Abdominal Pain Responder Rate | 93 | 58 |
Collected over 4 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 50mg BID | 0/307 (0%) | 6/307 (2%) | 45/307 (14.7%) |
| Placebo | 0/299 (0%) | 0/299 (0%) | 5/299 (1.7%) |
| Event | 50mg BID | Placebo |
|---|---|---|
| Panick AttackPsychiatric disorders | 1/307 | 0/299 |
| Alcohol withdrawal syndromwPsychiatric disorders | 1/307 | 0/299 |
| Major DepressionPsychiatric disorders | 1/307 | 0/299 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/307 | 0/299 |
| Pineal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/307 | 0/299 |
| MigraineNervous system disorders | 1/307 | 0/299 |
| Event | 50mg BID | Placebo |
|---|---|---|
| DiarrheaGastrointestinal disorders | 45/307 | 5/299 |
| Age, Continuous(years) | 50mg BID | Placebo | Total |
|---|---|---|---|
| Mean | 45 ± 13.38 | 44.9 ± 13.04 | 45 ± 13.20 |
| Sex: Female, Male(Participants) | 50mg BID | Placebo | Total |
|---|---|---|---|
| Female | 244 | 249 | 493 |
| Male | 63 | 50 | 113 |
| Ethnicity (NIH/OMB)(Participants) | 50mg BID | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 98 | 83 | 181 |
| Not Hispanic or Latino | 209 | 216 | 425 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 50mg BID | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian | 10 | 4 | 14 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 88 | 100 | 188 |
| White | 201 | 186 | 387 |
| More than one race | 8 | 7 | 15 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Body Mass Index (BMI)(kg/m^2) | 50mg BID | Placebo | Total |
|---|---|---|---|
| Mean | 29.88 ± 7.198 | 29.30 ± 6.442 | 29.60 ± 6.836 |
Showing the first 100 of 111 sites. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Oct 2015, a primary completion of Mar 2017 and a completion of Apr 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2020, 3 years 1 month after primary completion. A results delay was requested in Mar 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenapanor